Company profile EWTX

Edgewise Therapeutics Inc
Description of the company is not available.
Quarter analysis & expected interestLast update: February 08 2024 22:44:23.

After 39 days of this quarter the interest is at 94.0. Based on that we can calculate that during remaining 52 days it will total up to 219.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
201920
80
300.0% QoQ
228
185.0% QoQ
43
-81.1% QoQ
2020 89
345.0% YoY 107.0% QoQ
180
125.0% YoY 102.2% QoQ
94
-58.8% YoY -47.8% QoQ
119
176.7% YoY 26.6% QoQ
2021 289
224.7% YoY 142.9% QoQ
110
-38.9% YoY -61.9% QoQ
176
87.2% YoY 60.0% QoQ
172
44.5% YoY -2.3% QoQ
2022 220
-23.9% YoY 27.9% QoQ
84
-23.6% YoY -61.8% QoQ
287
63.1% YoY 241.7% QoQ
217
26.2% YoY -24.4% QoQ
2023 184
-16.4% YoY -15.2% QoQ
166
97.6% YoY -9.8% QoQ
135
-53.0% YoY -18.7% QoQ
228
5.1% YoY 68.9% QoQ
2024 94
-48.9% YoY -58.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Edgewise Therapeutics search interestLast update: February 08 2024 22:44:22.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 22:44:24.

The average 5 years interest of Edgewise Therapeutics was 12.32 per week.
The last year interest of Edgewise Therapeutics compared to the last 5 years has changed by 16.48%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 80.28%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for EDG-5506 clinical trials to provide analysis

Correlation between past revenue and EDG-5506 clinical trials search interest

There is not enough data for EDG-5506 clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for EDG-5506 clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 09 2023 07:52:42.

After 34 days of this quarter the interest is at 67.0. Based on that we can calculate that during remaining 58 days it will total up to 181.0.
Duchenne muscular dystrophy treatment expected interest is significantly lower compared to same quarter last year (-45.2%) but similar to previous quarter.

YearQ1Q2Q3Q4
2018 - - - 283
2019 564
99.3% QoQ
347
-38.5% QoQ
256
-26.2% QoQ
398
40.6% YoY 55.5% QoQ
2020 295
-47.7% YoY -25.9% QoQ
181
-47.8% YoY -38.6% QoQ
212
-17.2% YoY 17.1% QoQ
193
-51.5% YoY -9.0% QoQ
2021 223
-24.4% YoY 15.5% QoQ
191
5.5% YoY -14.3% QoQ
155
-26.9% YoY -18.8% QoQ
158
-18.1% YoY 1.9% QoQ
2022 211
-5.4% YoY 33.5% QoQ
288
50.8% YoY 36.5% QoQ
62
-60.0% YoY -78.5% QoQ
330
108.9% YoY 432.3% QoQ
2023 278
31.8% YoY -15.8% QoQ
267
-7.3% YoY -4.0% QoQ
255
311.3% YoY -4.5% QoQ
67
-79.7% YoY -73.7% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Duchenne muscular dystrophy treatment search interestLast update: November 09 2023 07:52:42.
Correlation coefficient between keyword and revenue is 0.37
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 09 2023 07:52:44.

The average 5 years interest of Duchenne muscular dystrophy treatment was 19.98 per week.
The last year interest of Duchenne muscular dystrophy treatment compared to the last 5 years has changed by 6.96%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -29.12%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Becker muscular dystrophy treatment to provide analysis

Correlation between past revenue and Becker muscular dystrophy treatment search interest

There is not enough data for Becker muscular dystrophy treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Becker muscular dystrophy treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for EDG-7500 cardiac disorders to provide analysis

Correlation between past revenue and EDG-7500 cardiac disorders search interest

There is not enough data for EDG-7500 cardiac disorders to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for EDG-7500 cardiac disorders to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precision medicine for muscle disorders to provide analysis

Correlation between past revenue and Precision medicine for muscle disorders search interest

There is not enough data for Precision medicine for muscle disorders to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precision medicine for muscle disorders to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Edgewise Therapeutics stock price to provide analysis

Correlation between past revenue and Edgewise Therapeutics stock price search interest

There is not enough data for Edgewise Therapeutics stock price to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Edgewise Therapeutics stock price to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Edgewise Therapeutics careers to provide analysis

Correlation between past revenue and Edgewise Therapeutics careers search interest

There is not enough data for Edgewise Therapeutics careers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Edgewise Therapeutics careers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Edgewise Therapeutics news to provide analysis

Correlation between past revenue and Edgewise Therapeutics news search interest

There is not enough data for Edgewise Therapeutics news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Edgewise Therapeutics news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Edgewise Therapeutics Colorado to provide analysis

Correlation between past revenue and Edgewise Therapeutics Colorado search interest

There is not enough data for Edgewise Therapeutics Colorado to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Edgewise Therapeutics Colorado to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for EWTX
Company name: Edgewise Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T08:00:00-04:00

PR Newswire
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

2026-05-12T11:05:00Z

GlobeNewswire
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

2026-05-07T08:00:00-04:00

PR Newswire
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

2026-05-04T08:00:00-04:00

PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

2026-04-01T08:00:00-04:00

PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

2026-03-17T14:32:59Z

Analyst Upgrades
JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $45

2026-03-17T12:25:10Z

Analyst Upgrades
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

2026-03-10T07:00:00-04:00

PR Newswire
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

2026-03-04T08:00:00-05:00

PR Newswire
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

2026-03-03T08:00:00-05:00

PR Newswire
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

2026-03-02T09:30:00-05:00

PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

2026-02-27T13:57:53Z

Analyst Upgrades
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $45

2026-02-26T08:00:00-05:00

PR Newswire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

2026-02-05T08:00:00-05:00

PR Newswire
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

2026-02-02T08:00:00-05:00

PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules